Abstract
Background A French retrospective observational cohort study conducted during the 2021/22 influenza season found that the high-dose influenza vaccine (HD) was more effective than standard-dose vaccines (SDs) in preventing influenza-related hospitalizations in the elderly. The study continued during the 2022/23 season to obtain more accurate results and validate the findings during a different influenza season.
Material and methods Data from community-dwelling 65+ adults vaccinated with HD or SD during the 2022/23 vaccination campaign were extracted from the National Health database. Hospitalizations were recorded from 14 days after vaccination until 30 June 2023. HD and SD recipients were matched using a propensity score with an exact constraint on age, sex, vaccination week, and geographical region. Associations between vaccines and hospitalizations (influenza or non-influenza related) were assessed by estimating incidence rate ratios and converting them to HD vs SD vaccine relative effectiveness (rVE).
Results 675,412 HD recipients were matched to 2,701,648 SD recipients. The HD vs SD rVE for influenza-related hospitalizations was 27.39% [95%CI: 19.79;34.27]. It ranged from 22.65% [9.84;33.64] to 33.55% [21.19;43.98] across age groups, indicating that HD resulted in consistently better protection than SDs against influenza-related hospitalizations in all age groups, with the highest effect observed in 85+.
Conclusion Our study is the first to publish rVE data comparing HD and SD in France, for the 2022/23 influenza season. Its findings reaffirm the benefit of HD vs SD in reducing influenza-related hospitalizations in a real-world setting. HD could help reduce the burden of severe respiratory infections in the elderly.
Registration number: Not applicable.
Take-home message In France, during the 2022/23 influenza season, the high-dose vaccine has reduced influenza-related hospitalizations by 27.4% compared to standard-dose vaccines among community-dwelling 65+ adults, with a clinical benefit observed across all age groups.
Competing Interest Statement
HB, MCL, MD, CS, MML are Sanofi employees and may hold shares in the company. NA, BG & FR are HEVA employees, which received funding from Sanofi to run the study. PC reports to have participated in advisory committees organized by Sanofi and being a consultant for Sanofi. JG reports to have participated in advisory committees organized by GSK, MSD, Pfizer, and Sanofi. GG reports to have participated in advisory committees organized by Astellas, AstraZeneca, BioMerieux, MSD, Pfizer, Sanofi, Sanofi Pasteur, Sanofi Pasteur-MSD and Vifor, acted as consultant and speaker for these companies, and participated in congresses on invitation by Eisai, MSD, Novartis, Pfizer, Sanofi, and Vifor. AM reports to have participated in advisory committees organized by Sanofi, Seqirus, and Viatris, to be a speaker for Sanofi, Seqirus, Viatris and Novavax, and to be a member of the scientific board of the SFM (formerly known as GEIG). FP is the owner of Abelia Science which received funding from Sanofi for medical writing. LW has received consulting fees from HEVA, Sanofi and Pfizer for works outside the submitted work. OL reports to be a principal investigator in vaccine trials sponsored by Sanofi, MSD, Pfizer, GSK, Moderna. She received financial support for travel to medical congress and personal fees for participation in advisory boards for Sanofi, MSD, Pfizer, and GSK.
Funding Statement
The study was funded by Sanofi.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data supporting the study findings are part of the National Health Data System (SNDS, Systeme national des Donnees de Sante) and are available from the HDH (Health Data Hub https://www.health-data-hub.fr/). Restrictions apply to the availability of these data containing potentially identifying and sensitive patient information. Special permission to access these data for this study was granted by the ethics and scientific committee for health research, studies, and evaluations (CESREES, Comite Ethique et Scientifique pour les Recherches, les Etudes et les Evaluations dans le domaine de la Sante) (former CEREES) and the French data protection authority (Comite National de l'Informatique et des Libertes, CNIL). The study protocol obtained two consecutive authorizations from the French data protection authority CNIL (initial authorization: Decision No. DR-2022-049; substantial modifications authorization: Decision DR-2023-013). Informed consent was not required for the use of the anonymized secondary data, as mentioned in the Social Security Code, Article L161-28-1. All methods were performed in accordance with CNIL regulations and with REporting of studies Conducted using Observational Routinely-collected Data (RECORD) guidelines.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Additional information is available on justified request.
List of abbreviations
- AD
- associated diagnosis
- AIC
- Akaike information criterion
- ALD
- long-term disease (Affection Longue Durée)
- CI
- confidence interval
- COPD
- chronic pulmonary obstructive disease
- FDEp
- French social deprivation index
- FWER
- Family-wise Error Rate
- HD
- high-dose influenza vaccine
- ICD
- International Classification of Diseases 10th Revision
- IRR
- incidence rate ratio
- PD
- primary diagnosis
- RD
- related diagnosis
- rVE
- relative vaccine effectiveness
- SD
- standard-dose influenza vaccine
- SNDS
- French Health Data System (Système National Des Données de Santé)
- UTI
- urinary tract infections
- WHO
- World Health Organization